Similar Search Results

Pharmaceutical regulation in Europe and its impact on corporate R&D

Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9

expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically … assessing the impact of regulation on pharmaceutical R&D expenditures. Methods: We analyze a sample of 20 leading pharmaceutical … companies between 2000 and 2008. The share of sales in Europe serves as a proxy for the degree of pharmaceutical regulation. We …

Persistent link: https://www.econbiz.de/10010526909

Pharmaceutical regulation at the wholesale level and parallel trade

Birg, Laura - 2013

This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by …

Persistent link: https://www.econbiz.de/10010223101

Untersuchung des Pharmasektors durch die Europäische Kommission : branchenübergreifende Bedeutung für Kartell- und geistiges Eigentumsrecht

Besen, Marc; Mayer, Christian - In: Europäisches Wirtschafts- und Steuerrecht : EWS ; … 20 (2009) 1/2, pp. 28-31

Persistent link: https://www.econbiz.de/10003819278

Implications of future EU policy on the provision of medicines and on actors in the European pharmaceutical sector

Ginneken, Ewout van - 2010

Persistent link: https://www.econbiz.de/10008826274

Systematic implications of transatlantic regulatory cooperation and competition

Evenett, Simon J. (contributor) - 2010

Persistent link: https://www.econbiz.de/10009009947

Pharmaceutical regulation and health policy objectives

Birg, Laura - 2013

This paper analyzes a maximum price system and a reference price system in a vertical differentiation model with a brand-name drug and a generic. In particular, both instruments are compared with respect to their performance in reducing public expenditure, limiting financial exposure of...

Persistent link: https://www.econbiz.de/10010224844